Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot FDA News Management Comments

Aimmune Therapeutics (AIMT) PT Raised to $58 at RBC CapitalMarch 26, 2019 6:27 AM Baird Incrementally Positive on Aimmune Therapeutics (AIMT) ARTEMIS Topline ReadoutMarch 25, 2019 12:52 PM European Phase 3 Trial of Aimmune Therapeutics’ AR101 Meets Primary EndpointMarch 25, 2019 8:00 AM